Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 May;43(5):1189-91.
doi: 10.1128/AAC.43.5.1189.

Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model

M H Cynamon  1 , S P Klemens, C A Sharpe, S Chase
Affiliations

Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model

M H Cynamon et al. Antimicrob Agents Chemother. 1999 May.

Abstract

The activities of linezolid, eperezolid, and PNU-100480 were evaluated in a murine model of tuberculosis. Approximately 10(7) viable Mycobacterium tuberculosis ATCC 35801 organisms were given intravenously to 4-week-old outbred CD-1 mice. In the first study, treatment was started 1 day postinfection and was given by gavage for 4 weeks. Viable cell counts were determined from homogenates of spleens and lungs. PNU-100480 was as active as isoniazid. Linezolid was somewhat less active than PNU-100480 and isoniazid. Eperezolid had little activity in this model. In the next two studies, treatment was started 1 week postinfection. A dose-response study was performed with PNU-100480 and linezolid (both at 25, 50, and 100 mg/kg of body weight). PNU-100480 was more active than linezolid, and its efficacy increased with an escalation of the dose. Subsequently, the activity of PNU-100480 alone and in combination with rifampin or isoniazid was evaluated and was compared to that of isoniazid-rifampin. The activity of PNU-100480 was similar to that of isoniazid and/or rifampin in the various combinations tested. Further evaluation of these oxazolidinones in the murine test system would be useful prior to the development of clinical studies with humans.

PubMed Disclaimer

References

    1. Ashtekar D R, Costa-Periera R, Shrinivasan T, Iyyer R, Vishvanathan N, Rittel W. Oxazolidinone, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 1991;14:465–471. - PubMed
    1. Barbachyn M R, Brickner S J, Ford C W, Glickman S, Grega K D, Hendges S K, Kilburn J O, Toops D S, Ulanowicz D A, Zurenko G E. Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1995. Synthesis and structure-activity relationships of new tropone-substituted oxazolidinone antibacterial agents, abstr. F206; p. 149.
    1. Barbachyn M R, Hutchinson D K, Brickner S J, Cynamon M H, Kilburn J O, Klemens S P, Glickman S E, Grega K C, Hendges S K, Toops D S, Ford C W, Zurenko G E. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem. 1996;39:680–685. - PubMed
    1. Bostic G D, Perri M B, Thal L A, Zervos M J. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect Dis. 1998;30:109–112. - PubMed
    1. Eustice D C, Feldman G M, Zajac I, Slee A M. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother. 1988;32:1218–1222. - PMC - PubMed

Publication types